Novartis is stepping on the cGAS. Three years after securing an option on an IFM Therapeutics subsidiary, the Swiss drugmaker has accelerated into the deal and paid $90 million upfront for small ...
IFM Therapeutics is hiving off its NLRP3 stable into a subsidiary dubbed IFM Tre. The new unit, which starts out with $31 million in series A funding, expects to bring its lead asset into phase 1 in ...
BOCA RATON, Fla. & MELBOURNE, Australia & LAS VEGAS--(BUSINESS WIRE)--DigitalBridge Group, Inc. (NYSE: DBRG) (“DigitalBridge”) and IFM Investors today announced they have completed their previously ...
Aspiring to become the leader in inflammasome-targeted therapeutics, Novartis will acquire IFM Tre, a subsidiary of Boston-based IFM Therapeutics, in a deal worth up to $1.6 billion. The purchase ...
Novartis is to buy US biotech IFM Tre in a deal worth up to $1.575 billion, adding a potential drug for the fatty liver disease known as NASH to its pipeline. IFM Tre is a subsidiary of cancer biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results